Premium
Effects of a 5‐HT 4 receptor agonist on oesophageal function and gastro‐oesophageal reflux: studies using combined impedance‐manometry and combined impedance‐pH
Author(s) -
TUTUIAN R.,
MAINIE I.,
ALLAN R.,
HARGREAVES K.,
AGRAWAL A.,
FREEMAN J.,
GALE J.,
CASTELL D. O.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02968.x
Subject(s) - tegaserod , medicine , postprandial , placebo , agonist , reflux , bolus (digestion) , cisapride , crossover study , gastroenterology , irritable bowel syndrome , receptor , pathology , alternative medicine , disease , insulin
Summary Background 5‐HT 4 receptor agonists are used as promotility agents of the stomach, small and large intestine. There is limited information on the influence of 5‐HT 4 receptor agonists on oesophageal function and gastro‐oesophageal reflux. Aim To evaluate the effects of tegaserod, a 5‐HT 4 agonist on oesophageal function using impedance‐manometry and postprandial reflux using impedance‐pH monitoring. Methods Twenty healthy volunteers were enrolled in a double‐blind randomized three‐period crossover placebo‐controlled study. Impedance‐manometry and impedance‐pH monitoring after a refluxogenic meal were performed at baseline and after 2 days of dosing with tegaserod 6 mg b.d. or placebo. Multichannel intraluminal impedance‐EM recorded pressure and bolus transit data during standardized swallows. Multichannel intraluminal impedance‐pH monitoring recorded the number of 2‐h postprandial acid and non‐acid reflux episodes. Results We found no significant difference in distal oesophageal amplitude when subjects received placebo (median 94.5; range: 53–243 mmHg) or tegaserod (93.6; 43–216 mmHg). Bolus transit time was similar during dosing with placebo (7.1; 5.3–9.4 s) and tegaserod (7.2; 5.9–11.1 s). We observed similar numbers of acid and non‐acid reflux episodes during dosing with placebo (5; 0–15 and 3; 0–18, respectively) and tegaserod (2; 0–11 and 4; 0–19, respectively). Conclusion Tegaserod, a 5‐HT 4 receptor agonist does not change oesophageal motility and gastro‐oesophageal reflux parameters in healthy volunteers.